Analysis of the efficacy and effects of tenofovir alafenamide fumarate tablets (Vemlidy)

Tenofovir alafenamide fumarate tablets (Vemlidy/Vemlidy) is an antiviral drug used to treat adult patients with chronic hepatitis B (HBV). It is a nucleotide reverse transcriptase inhibitor (NtRTI). By blocking the key link of hepatitis B virus DNA replication, it inhibits virus proliferation and helps patients achieve sustained virus suppression and improvement of liver function. As a new generation improved dosage form of Tenofovir, Veride has higher tissue targeting and lower systemic exposure levels, thus achieving a better balance between efficacy and safety.

Compared with the earlier tenofovir disoproxil disoproxil (TDF), tenofovir alafenamide fumarate (TAF) can achieve similar or even greater viral suppression at a lower dose. TAF releases active metabolites after activation in hepatocytes and maintains low concentrations in the blood circulation, thereby significantly reducing adverse effects on the kidneys and bone density. This means that hepatitis B patients who take it long-term can achieve good viral control while reducing risks such as decreased kidney function and osteoporosis.

In terms of treatment goals, the core role of Veride is to achieve the long-term stable reduction of HBV DNA levels, improve liver function indicators (such as ALT, AST) and slow down the progression of liver fibrosis. Some patients can achieve a decrease in hepatitis B surface antigen (HBsAg) under long-term treatment, and may even have a chance of functional cure. It is also one of the first-line oral drugs in the international guidelines for chronic hepatitis B.

In addition, tenofovir alafenamide fumarate tablets show a low risk of drug interactions in terms of metabolic characteristics and are suitable for patients with multiple complications. For example, patients with mild renal impairment, the elderly, or patients taking other antiviral drugs for a long time can tolerate it well. Its once-daily oral regimen also improves patient compliance and simplifies long-term medication management.

Reference materials:https://www.vemlidyhcp.com/